{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-009696","form_type":"8-K","ticker":"QURE","cik":"0001590560","company_name":"uniQure N.V.","filed_at":"2024-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.672712+00:00","generated_at":"2026-05-31T22:35:42.235063+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"uniQure announces positive interim Phase I/II data for AMT-130: 80% slowing of Huntington's progression at high dose","bullets":["High-dose AMT-130 showed 80% slowing of cUHDRS decline vs. external control at 24 months (p=0.007).","CSF neurofilament light chain reduced 11% from baseline at 24 months in treated patients (p=0.02).","AMT-130 received first-ever RMAT designation for Huntington's disease from FDA.","Company expects to meet with FDA in H2 2024 to discuss expedited development and accelerated approval.","No new AMT-130-related serious adverse events; safety profile manageable at both doses."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-009696","json":"https://secwatch.observer/filing/0001558370-24-009696.json","markdown":"https://secwatch.observer/filing/0001558370-24-009696.md","text":"https://secwatch.observer/filing/0001558370-24-009696.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590560/000155837024009696/0001558370-24-009696-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590560/000155837024009696/qure-20240709x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T22:35:42.235063+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}